Australia markets closed

Herborium Group, Inc. (HBRM)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.00030.0000 (0.00%)
At close: 03:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.0003
Open0.0003
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.0003 - 0.0003
52-week range0.0002 - 0.0013
Volume1,499,676
Avg. volume19,232,697
Market cap660,885
Beta (5Y monthly)100.76
PE ratio (TTM)0.00
EPS (TTM)0.1150
Earnings date21 July 2022
Forward dividend & yieldN/A (2.43%)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Herborium®’ Group Half Year Update

    Debt Elimination, Maintaining Sales and New Initiatives In FocusHouston, July 21, 2022 (GLOBE NEWSWIRE) -- Houston, Texas, 07/21/2022. Herborium Group, Inc. (OTC Pink: HBRM), a Botanical Therapeutics Company and provider of unique, all botanical medicinal, beauty and wellness products with a clinically validated records of efficacy and safety, announced today the following accomplishments for the first half of 2022. The Company also shares with Investors the plan for the remaining months of the

  • GlobeNewswire

    Herborium® Enters $220Billion Digital Content Market

    The First Stage of Transition Into the “Content Plus Product” Entity To Be Deployed in Fourth Quarter of 2022Houston, May 10, 2022 (GLOBE NEWSWIRE) -- Houston, Texas, 05/10/2022. Herborium Group, Inc. (OTC Pink: HBRM), a Botanical Therapeutics Company and the provider of unique, all botanical medicinal, beauty and wellness products with a clinically validated records of efficacy and safety, announced today that it officially commenced its transition into “Content Plus Product Company” initially

  • GlobeNewswire

    Herborium® Surpasses Million Dollar Sales Mark; Reduces Outstanding Debt and Dilution

    Houston , Texas, May 03, 2022 (GLOBE NEWSWIRE) -- Houston, Texas,05.03/ 2022. Herborium Group, Inc. (OTC Pink: HBRM), a Botanical Therapeutics Company and the provider of unique, all botanical medicinal, beauty and wellness products with a clinically validated records of efficacy and safety, announced today that the Company ended 2021 with a record sale surpassing $1Million as reported in Annual Report . 2021. This marks the fifth consecutive Positive Revenues Year . This positive trend is exten